Latest Reimbursement News

Worley Limited reveals the ongoing Middle East conflict is causing significant project delays and an estimated $30 to $40 million hit to FY26 underlying EBITA, prompting a revision to its growth outlook.

Channel Infrastructure has locked in a government contract for 93 million litres of additional diesel storage at Marsden Point, adding about $8 million revenue in 2026 and reinforcing its role in New Zealand’s fuel security.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.

Diatreme Resources is consolidating its Far North Queensland silica assets by selling the Cape Flattery Silica Project to its joint venture with Sibelco, securing $7.4 million in fresh capital and streamlining project ownership ahead of key development milestones.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

EBR Systems has reported a significant increase in commercial implantations of its WiSE System in Q1 2026, more than doubling case volumes from the previous quarter and projecting preliminary revenue between US$2.25 million and US$2.36 million.

Imricor Medical Systems has submitted its NorthStar Mapping System for FDA pediatric label expansion, aiming to accelerate adoption in over 250 US children’s hospitals and broaden its commercial footprint.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.

Collins Foods has agreed to transfer 20 of its 27 Australian Taco Bell restaurants to a new partnership involving Taco Bell’s parent company, marking a decisive step in its strategic exit from the brand.

Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.